These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 28095679)

  • 1. Non-Naturally Occurring Small Molecule Microtubule-Stabilizing Agents: A Potential Tactic for CNS-Directed Therapies.
    Ballatore C; Brunden KR; Trojanowski JQ; Lee VM; Smith AB
    ACS Chem Neurosci; 2017 Jan; 8(1):5-7. PubMed ID: 28095679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain-penetrant, orally bioavailable microtubule-stabilizing small molecules are potential candidate therapeutics for Alzheimer's disease and related tauopathies.
    Lou K; Yao Y; Hoye AT; James MJ; Cornec AS; Hyde E; Gay B; Lee VM; Trojanowski JQ; Smith AB; Brunden KR; Ballatore C
    J Med Chem; 2014 Jul; 57(14):6116-27. PubMed ID: 24992153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered microtubule dynamics in neurodegenerative disease: Therapeutic potential of microtubule-stabilizing drugs.
    Brunden KR; Lee VM; Smith AB; Trojanowski JQ; Ballatore C
    Neurobiol Dis; 2017 Sep; 105():328-335. PubMed ID: 28012891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microtubule-stabilizing agents as potential therapeutics for neurodegenerative disease.
    Brunden KR; Trojanowski JQ; Smith AB; Lee VM; Ballatore C
    Bioorg Med Chem; 2014 Sep; 22(18):5040-9. PubMed ID: 24433963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of Brain-Penetrant Pyrimidine-Containing Molecules with Differential Microtubule-Stabilizing Activities Developed as Potential Therapeutic Agents for Alzheimer's Disease and Related Tauopathies.
    Kovalevich J; Cornec AS; Yao Y; James M; Crowe A; Lee VM; Trojanowski JQ; Smith AB; Ballatore C; Brunden KR
    J Pharmacol Exp Ther; 2016 May; 357(2):432-50. PubMed ID: 26980057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential for Treatment of Neurodegenerative Diseases with Natural Products or Synthetic Compounds that Stabilize Microtubules.
    Miller JH; Das V
    Curr Pharm Des; 2020; 26(35):4362-4372. PubMed ID: 32564745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies.
    Brunden KR; Yao Y; Potuzak JS; Ferrer NI; Ballatore C; James MJ; Hogan AM; Trojanowski JQ; Smith AB; Lee VM
    Pharmacol Res; 2011 Apr; 63(4):341-51. PubMed ID: 21163349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microtubule-Stabilizing 1,2,4-Triazolo[1,5-
    Alle T; Varricchio C; Yao Y; Lucero B; Nzou G; Demuro S; Muench M; Vuong KD; Oukoloff K; Cornec AS; Francisco KR; Caffrey CR; Lee VM; Smith AB; Brancale A; Brunden KR; Ballatore C
    J Med Chem; 2023 Jan; 66(1):435-459. PubMed ID: 36534051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microtubule stabilizing agents as potential treatment for Alzheimer's disease and related neurodegenerative tauopathies.
    Ballatore C; Brunden KR; Huryn DM; Trojanowski JQ; Lee VM; Smith AB
    J Med Chem; 2012 Nov; 55(21):8979-96. PubMed ID: 23020671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic, pharmacodynamic and metabolic characterization of a brain retentive microtubule (MT)-stabilizing triazolopyrimidine.
    Cornec AS; James MJ; Kovalevich J; Trojanowski JQ; Lee VM; Smith AB; Ballatore C; Brunden KR
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4980-4982. PubMed ID: 25819095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microtubule-stabilising drugs for therapy of Alzheimer's disease and other neurodegenerative disorders with axonal transport impairments.
    Trojanowski JQ; Smith AB; Huryn D; Lee VM
    Expert Opin Pharmacother; 2005 May; 6(5):683-6. PubMed ID: 15934894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the Structure-Activity Relationship of Microtubule-Targeting 1,2,4-Triazolo[1,5-
    Oukoloff K; Nzou G; Varricchio C; Lucero B; Alle T; Kovalevich J; Monti L; Cornec AS; Yao Y; James MJ; Trojanowski JQ; Lee VM; Smith AB; Brancale A; Brunden KR; Ballatore C
    J Med Chem; 2021 Jan; 64(2):1073-1102. PubMed ID: 33411523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and evaluation of photoactivatable derivatives of microtubule (MT)-active [1,2,4]triazolo[1,5-a]pyrimidines.
    Oukoloff K; Kovalevich J; Cornec AS; Yao Y; Owyang ZA; James M; Trojanowski JQ; Lee VM; Smith AB; Brunden KR; Ballatore C
    Bioorg Med Chem Lett; 2018 Jul; 28(12):2180-2183. PubMed ID: 29764743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases.
    Barchet TM; Amiji MM
    Expert Opin Drug Deliv; 2009 Mar; 6(3):211-25. PubMed ID: 19290842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multitargeted Imidazoles: Potential Therapeutic Leads for Alzheimer's and Other Neurodegenerative Diseases.
    Cornec AS; Monti L; Kovalevich J; Makani V; James MJ; Vijayendran KG; Oukoloff K; Yao Y; Lee VM; Trojanowski JQ; Smith AB; Brunden KR; Ballatore C
    J Med Chem; 2017 Jun; 60(12):5120-5145. PubMed ID: 28530811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Central nervous system penetration for small molecule therapeutic agents does not increase in multiple sclerosis- and Alzheimer's disease-related animal models despite reported blood-brain barrier disruption.
    Cheng Z; Zhang J; Liu H; Li Y; Zhao Y; Yang E
    Drug Metab Dispos; 2010 Aug; 38(8):1355-61. PubMed ID: 20427691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hybrid molecules incorporating natural products: applications in cancer therapy, neurodegenerative disorders and beyond.
    Decker M
    Curr Med Chem; 2011; 18(10):1464-75. PubMed ID: 21428895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloid peptide toxicity and microtubule-stabilizing drugs.
    Michaelis ML; Chen Y; Hill S; Reiff E; Georg G; Rice A; Audus K
    J Mol Neurosci; 2002; 19(1-2):101-5. PubMed ID: 12212764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk in CNS drug discovery: focus on treatment of Alzheimer's disease.
    Pritchard JF
    BMC Neurosci; 2008 Dec; 9 Suppl 3(Suppl 3):S1. PubMed ID: 19090998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospects for antiapoptotic drug therapy of neurodegenerative diseases.
    Waldmeier PC
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Apr; 27(2):303-21. PubMed ID: 12657369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.